

West of Scotland Cancer Network : Skin Cancer MCN Work Plan 2026/2027

	Actions Required	Lead	Due Date
1.	Continue to engage with the Regional MDT Improvement Programme to optimise operational efficiency and effectiveness of the MDT		
1.1	Work with MDT programme Board and eHealth colleagues to progress development of the MDT digital system ready for regional implementation, utilising the agreed tumour-specific dataset for skin cancers.	MCN Clinical Lead MCN&I Manager Local MDT Leads MCN Members	In line with MDT system timelines
1.2	<i>Define and agree outputs/reports to be generated from the MDT system.</i>	<i>Included in overarching regional delivery plan.</i>	In line with MDT system timelines
2.	Develop a pre-habilitation programme tailored for patients undergoing immunotherapy		
2.1	Undertake literature review, liaise with national experts and summarise key findings.	MCN Clinical Lead MCN&I Manager MCN Members NHS Library services	November 2026
2.2	Work with the WoS team to develop an immunotherapy-specific pre-hab programme that could be recommended at the time of diagnosis and referral on for further surgery and oncology opinions.	MCN Clinical Lead MCN&I Manager MCN Members	March 2027
3.	Undertake horizon scanning to ensure that skin cancer services are prepared for any major changes in service provision		
3.1	Link in with oncology colleagues (and pharma companies as required) to identify, pre SMC approval, any major changes to the skin cancer SACT pathways.	MCN Clinical Lead MCN&I Manager MCN Members	June 2026
3.2	Proactively establish SLWG to consider the impact of new therapeutic options on all specialties involved in skin cancer care and plan for implementation into clinical practice.	MCN Clinical Lead MCN&I Manager SLWG	As required
4.	Develop and maintain regional /national clinical guidelines to optimise patient care and lead on the development of national guidelines through collaboration with the Scottish Cancer Network (SCN) and colleagues in SCAN/NCA		
4.1	Co-ordinate the review of clinical management guidelines (CMGs) and clinical guidance documents (CGDs) in line with WoSCAN SOP. CMGs <ul style="list-style-type: none"> Cutaneous Malignant Melanoma (SACT only element has been developed by SCN) 	MCN Clinical Lead MCN&I Manager MCN Members	Jul 26

	Actions Required	Lead	Due Date
	<ul style="list-style-type: none"> Scottish Consensus CMG – Squamous Cell Carcinoma Basal Cell Carcinoma 		Nov 26 Feb 27
4.2	CGDs <ul style="list-style-type: none"> Cutaneous Melanoma National Follow-up Guideline Skin Cancer Squamous Cell Carcinoma National Follow-up Guideline Identification of Correct Site for Further Surgery or Radiotherapy Skin Cancer Basal Cell Carcinoma Regional Follow-up Guideline Regional Consensus Documents <ul style="list-style-type: none"> Atypical Spitz (NEW) 		May 26 Aug 26 Sep 26 Feb 27 Jul 26
4.3	Clinical Management Pathway (CMP) <ul style="list-style-type: none"> Following confirmation from the Medicines Governance team that all SACT protocols and regimens are in place, seek MCN approval of SACT-only CMP and complete CMP coversheet for submission to PASG Upload PASG approved CMP onto WoSCAN intranet and archive the SACT section of current regional CMG for Cutaneous Malignant Melanoma 	MCN Clinical Lead MCN&I Manager MCN Members SCN	Sept 26 Sept 26
5. Continue to lead the Neo-adjuvant SLWG to finalise the neo-adjuvant immunotherapy pathways for patients with cutaneous melanoma			
5.1	Liaise with radiology colleagues across the region to obtain radiology input to, and agreement of, the proposed pathway for marking lymph nodes in neoadjuvant cases.	MCN Clinical Lead MCN&I Manager SLWG Advisory Board	Apr 26
5.2	Circulate proposed pathways to wide MCN for comment.		May 26
5.3	Collate comments and update draft as required.		Jun 26
5.4	Obtain Advisory Board approval of final draft and publish on WoSCAN intranet site		Jul 26
6. Optimise clinical pathways for patients with non-melanoma skin cancer			
6.1	Engage with the NHSGGC working group optimising the skin cancer pathway as this involves the regional Oncology and Plastics services. Extend key points around regional services as well as general learning points to other Boards in the MCN.	MCN Clinical Lead MCN&I Manager MCN Members	Oct26
6.2	Engage with the clinical oncologists to consider the prospects of adjuvant immunotherapy for SCC, including pathways where required, and consider service implications	MCN Clinical Lead MCN&I Manager MCN Members	As required

	Actions Required	Lead	Due Date
7.	Promote a robust regional audit and research programme coordinated through the Skin Cancer MCN Research Subgroup to generate data and outcomes to improve patient pathways		
7.1	<ul style="list-style-type: none"> Identify areas where there is currently a lack of clinical evidence to support practice Support groups from all interested specialties in obtaining appropriate data to generate suitable analysis Where appropriate, encourage regional collaboration on projects to achieve patient numbers and standardise outcomes in cancer care across the network 	MCN Research SubGroup MCN&I Manager Information Analyst	Mar 27
7.2	Continue the rolling retrospective audit of imaging follow-up in patients with melanoma and identify any actions arising from the audit	MCN Clinicians	Mar 27
7.3	Establish an up-to date register of current clinical trial activity and encourage colleagues within the West of Scotland to actively participate in large, national multi-centre trials	MCN Research SubGroup MCN&I Manager	Mar 27
7.4	Provide regular MCN-wide updates (via MCN Newsletter) on current and pending clinical trials to encourage recruitment	MCN Research SubGroup MCN&I Manager	Mar 27
8.	Use cancer data to drive improvement in quality of care and outcomes		
8.1	Review QPI audit findings to identify variation in practice and highlight exceptions. <ul style="list-style-type: none"> Performance Summary Returns Assessed RCOG exception report produced Governance review and Interrogation of QPI exceptions Agreement of actions for inclusion in annual audit reports Input to the production of Annual Audit Report 	MCN Clinical Lead MCN&I Manager Information Manager Information Analyst	Jan 27
8.2	Identify requirements for further data analysis to aid understanding of variance and develop action/improvement plans.	MCN Clinical Lead MCN&I Manager MCN Clinicians Information Analyst	Jan 27
8.3	Monitor and ensure progress with regional and local board action/improvement plans. <ul style="list-style-type: none"> Conclusion of actions from QPI Exception Report 	MCN Clinical Lead MCN&I Manager MCN Members	Ongoing
8.4	Work with the local audit teams to explore where data collected for QPIs can provide insight into performance challenges not captured through QPI reporting.	MCN Clinical Lead MCN&I Manager MCN Members Information Analyst	Ongoing

	Actions Required	Lead	Due Date
9.	Re-establish the skin specialist nurses group as an independent subgroup of the Skin Cancer MCN		
9.1	Formally reconstitute Nurses Group, with new Chair and secretariat identified.	MCN Clinical Lead MCN&I Manager CNSs	May 26
9.2	Review initial workstreams and identify specific objectives to be progressed in the coming year.	MCN Clinical Lead MCN&I Manager CNSs	Jun 26
10.	Deliver regional education event which facilitates review of clinical audit data and promotes shared learning of current best practice and innovation		
10.1	Develop a focused programme for the event, addressing relevant key issues.	MCN Clinical Lead MCN&I Manager	Apr 26
10.2	Establish data requirements for the event and identify any arising from the event. <ul style="list-style-type: none"> • Liaise with information team regards audit presentation requirements • Liaise with information team if any further audit opportunities identified • Ensure appropriate data sharing agreements issued, completed, agreed and passed to Information Team 	MCN Clinical Lead MCN&I Manager Information Analyst	Jul 26 Sep 26 Sep 26
10.3	Develop action plans arising from event and monitor progress of agreed actions. <ul style="list-style-type: none"> • Record actions arising from discussion at event • Develop action plans of same • Issue action plans as appropriate • Monitor progress of actions recorded 	MCN Clinical Lead MCN&I Manager	Sep 26
11.	Maintain regional service configuration map for skin cancers		
11.1	Update audit and activity data annually in line with QPI report publication and refresh as per any changes in configuration.	MCN&I Manager Information Analyst	Dec 26
12.	Watching brief		
12.1	Work with the Boards within the network to identify possible clinical pathway changes or improvements that might be realised with the use of the Digital Dermatology Programme and Active Clinical Referral Triage (ACRT). Focus will be on time to first treatment for patients with melanoma.	MCN Clinical Lead MCN&I Manager Advisory Board Information Analyst	Mar 27